Targeting of VPS18 by the lysosomotropic agent RDN reverses TFE3-mediated drug resistance

[1]  S. Muller,et al.  Lysosomes as a therapeutic target , 2019, Nature Reviews Drug Discovery.

[2]  R. Puertollano,et al.  TFEB and TFE3: Linking Lysosomes to Cellular Adaptation to Stress. , 2016, Annual review of cell and developmental biology.

[3]  Y. Assaraf,et al.  Lysosomes as mediators of drug resistance in cancer. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[4]  Rik van der Kant,et al.  Characterization of the Mammalian CORVET and HOPS Complexes and Their Modular Restructuring for Endosome Specificity* , 2015, The Journal of Biological Chemistry.

[5]  Huiqing Yuan,et al.  A novel derivative of riccardin D induces cell death through lysosomal rupture in vitro and inhibits tumor growth in vivo. , 2013, Cancer letters.